Clinical Trials at the Summit
Jun 21, 2025
Las Vegas, NV, USA
Friday, June 20, 8:05 PM - 8:15 PM PST
Riad Sherif, MD, Oculis’ Chief Executive Officer will be presenting a corporate update.
Saturday, June 21
11:11 AM - 11:15 AM PST
Arshad M. Khanani, MD, member of the Oculis Board of Directors, Chairperson of Oculis Retina Scientific Advisory Board and DIAMOND Steering Committee, will be presenting “Efficacy and Safety of Privosegtor in Acute Optic Neuritis: Results from a Multicenter, Randomized, Double Blinded Study (ACUITY)” on behalf of co-authors
12:45 PM – 1:05 PM PST
Snehal Shah, Oculis’ President of R&D, will be participating, as a panelist, in the discussion “Designing Pivotal Trials Aligned with Evolving Regulatory Guidance”
2:41 PM - 2:45 PM PST
Baruch D. Kuppermann, MD,PhD, member of Oculis Scientific Advisory Board and DIAMOND Steering Committee, will be presenting “BCVA and CST Improvements over 12 Weeks with OCS-01 Eye Drops in DME in the DIAMOND Stage 1 Trial” on behalf of co-authors
2:45 PM - 2:49 PM PST
Sharon Klier, MD, Oculis’ Chief Development Officer, will be presenting “Assessing the Efficacy and Safety of OCS-01 Eye Drops for the Management of DME: The DIAMOND Trial Program”
5:25 PM – 6:19 PM PST
Riad Sherif, MD, Oculis’ Chief Executive Officer, will be participating, as a panelist, in the discussion “First Time Results of Clinical Trials”
Riad Sherif, MD, Oculis’ Chief Executive Officer will be presenting a corporate update.
Saturday, June 21
11:11 AM - 11:15 AM PST
Arshad M. Khanani, MD, member of the Oculis Board of Directors, Chairperson of Oculis Retina Scientific Advisory Board and DIAMOND Steering Committee, will be presenting “Efficacy and Safety of Privosegtor in Acute Optic Neuritis: Results from a Multicenter, Randomized, Double Blinded Study (ACUITY)” on behalf of co-authors
12:45 PM – 1:05 PM PST
Snehal Shah, Oculis’ President of R&D, will be participating, as a panelist, in the discussion “Designing Pivotal Trials Aligned with Evolving Regulatory Guidance”
2:41 PM - 2:45 PM PST
Baruch D. Kuppermann, MD,PhD, member of Oculis Scientific Advisory Board and DIAMOND Steering Committee, will be presenting “BCVA and CST Improvements over 12 Weeks with OCS-01 Eye Drops in DME in the DIAMOND Stage 1 Trial” on behalf of co-authors
2:45 PM - 2:49 PM PST
Sharon Klier, MD, Oculis’ Chief Development Officer, will be presenting “Assessing the Efficacy and Safety of OCS-01 Eye Drops for the Management of DME: The DIAMOND Trial Program”
5:25 PM – 6:19 PM PST
Riad Sherif, MD, Oculis’ Chief Executive Officer, will be participating, as a panelist, in the discussion “First Time Results of Clinical Trials”